551 related articles for article (PubMed ID: 32020398)
1. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
[TBL] [Abstract][Full Text] [Related]
2. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
[TBL] [Abstract][Full Text] [Related]
3. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
[TBL] [Abstract][Full Text] [Related]
4. Reliability, Validity, and Reader Acceptance of LI-RADS-An In-depth Analysis.
Barth BK; Donati OF; Fischer MA; Ulbrich EJ; Karlo CA; Becker A; Seifert B; Reiner CS
Acad Radiol; 2016 Sep; 23(9):1145-53. PubMed ID: 27174029
[TBL] [Abstract][Full Text] [Related]
5. Can absolute arterial phase hyperenhancement improve sensitivity of detection of hepatocellular carcinoma in indeterminate nodules on CT?
Zafar S; Elbanna KY; Todd AWM; Guimaraes L; O'Brien C; Goel A; Kim TK; Khalili K
Eur Radiol; 2024 Apr; 34(4):2256-2268. PubMed ID: 37775590
[TBL] [Abstract][Full Text] [Related]
6. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
[TBL] [Abstract][Full Text] [Related]
8. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma.
Cunha GM; Hasenstab KA; Delgado T; Ichikawa S; Lee MH; Dautt Medina PM; Kim SJ; Lee YH; Kwon H; Sirlin CB; Fowler KJ
Eur Radiol; 2021 Oct; 31(10):7594-7604. PubMed ID: 33876298
[TBL] [Abstract][Full Text] [Related]
9. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
Yao S; Wei Y; Ye Z; Chen J; Duan T; Zhang Z; Song B
J Magn Reson Imaging; 2024 Jun; 59(6):2060-2070. PubMed ID: 34121266
[TBL] [Abstract][Full Text] [Related]
12. Computer-aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR images following liver imaging reporting and data system (LI-RADS).
Kim Y; Furlan A; Borhani AA; Bae KT
J Magn Reson Imaging; 2018 Mar; 47(3):710-722. PubMed ID: 28556283
[TBL] [Abstract][Full Text] [Related]
13. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
Li L; Zheng W; Wang J; Han J; Guo Z; Hu Y; Li X; Zhou J
AJR Am J Roentgenol; 2022 Sep; 219(3):434-443. PubMed ID: 35441534
[No Abstract] [Full Text] [Related]
14. Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System.
Wang JY; Feng SY; Yi AJ; Zhu D; Xu JW; Li J; Cui XW; Dietrich CF
Ultrasound Med Biol; 2020 May; 46(5):1216-1223. PubMed ID: 32115307
[TBL] [Abstract][Full Text] [Related]
15. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
17. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
[TBL] [Abstract][Full Text] [Related]
18. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.
Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
PLoS One; 2020; 15(11):e0242344. PubMed ID: 33186378
[TBL] [Abstract][Full Text] [Related]
19. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
[TBL] [Abstract][Full Text] [Related]
20. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
